CAS Number 5108-94-1 ChemSpider 4445527 KEGG C14242 | PubChem CID 5282364 UNII 1G3TKH1O14 Molar mass 316.4345 g/mol | |
 | ||
Synonyms SC-6924; Manvene; Anvene; 3-Methoxy-16α-methylestra-1,3,5(10)-triene-16β,17β-diol; 16α-Methylestriol 3-methyl ether; 16β-Hydroxy-16α-methylestradiol 3-methyl ether | ||
Mytatrienediol (developmental code name SC-6924; former tentative trade names Manvene, Anvene), also known as 16α-methyl-16β-epiestriol 3-methyl ether or 16β-hydroxy-16α-methylestradiol 3-methyl ether, is a semisynthetic, steroidal, weak estrogen and estrogen ether derived from estriol that was developed in the late 1950s but was never marketed. It was investigated as a mildly estrogenic drug for men to treat atherosclerosis and improve serum lipid profiles and reduce the risk of myocardial infarction. However, like other estrogens, mytatriendiol was found in clinical trials to produce estrogenic side effects such as breast pain and gynecomastia in men, and its side effects ultimately precluded its use. The drug was also studied to treat bone pain in patients with multiple myeloma, metastatic bone disease, and osteoporosis, with effectiveness seen.